Navigation Links
Study provides hope that some transplant patients could live free of anti-rejection drugs
Date:8/20/2007

STANFORD, Calif. - People with organ transplants, resigned to a lifetime of anti-rejection drugs, may now have reason to hope for a respite, say researchers at Lucile Packard Children's Hospital and the Stanford University School of Medicine. Using a simple blood sample, the scientists have identified for the first time a pattern of gene expression shared by a small group of patients who beat the odds and remained healthy for years without medication.

The findings suggest that transplant recipients who share the same pattern of genes but are still on conventional medication may be able to reduce or eliminate their lifelong dependence on immunosuppressive drugs. The study may also help physicians determine how best to induce acceptance, or tolerance, of donor organs in all transplant patients, regardless of their gene expression profiles.

"We're very excited by the findings," said Minnie Sarwal, MD, PhD, a pediatric nephrologist at Packard Children's. "Most transplant patients who stop taking their medications will reject their organ. But now we have the chance of telling someone committed to a lifetime of drugs that it may be possible to minimize their exposure to the drugs."

Although the anti-rejection medications, known as immunosuppressants, tamp down the immune system enough to permit lifesaving organ transplants, their benefits come at a price. They also quash the body's natural response to dangerous invaders, such as bacteria and viruses, and to rogue cancer cells. Transplant physicians prescribing immunosuppressants to their patients walk a fine line between avoiding organ rejection and increasing the risk of infection and cancer.

Sarwal, associate professor of pediatrics at the medical school, is the senior author of the research, which will be published Aug. 20 in the advance online edition of the Proceedings of the National Academy of Sciences. She collaborated with physicians at Stanford and Packard Children's, as
'/>"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... QUINCY, Mass., Nov. 20 Following ...et Company removed from sale Shedd,s Country Crock...nd Shedd,s Country Crock ® Side Dishes DELUXE...lergen. ,, The following code dates and UPCs a...ide Dishes DELUXE Cheddar Broccoli Rice 21 oz, UPC...
(Date:11/20/2009)..., HAIFA, Israel, November 20 /PRNewswire-Fir...VSL.OB), http://www.CVSLMEDICAL.COM , a leading,d...logy, today announced that,the company,s Board of ...ons,in Europe, Canada and the Far East for its pro...licable for all angioplasty (PCTA) procedures. ,...
(Date:11/20/2009)...ations of exposure to formaldehyde used for embalm...n increased risk of death from myeloid leukemia, a...20 in the Journal of the National Cancer Institut...ty from lymphohematopoietic malignancies and brain...ndustry workers, all of whom may have worked with ...
(Date:11/20/2009)...save up to one-third buying 90-day supply, study f...) -- Buying a three-month supply of prescription d...month supply, according to a new study. , U.S. ...or 395 drugs between 2000 and 2005, and found that...of a one-month supply saved an average 29 percent ...
(Date:11/20/2009)... SPRINGFIELD, Mo., Nov. 20 Missour...al Missouri regions will now have the option to ch...ched Tuesday between Missouri Consolidated Health ...e Southwest and South Central Missouri regions inc... Christian, Dade, Dallas, Douglas, Greene, Hickory...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2
...ve crafted a gene circuit that permits precise tun...hat should allow for more accurate analysis of the...ion. , This gene "dosing effect" is achieved by i...sts at The University of Texas M. D. Anderson Canc...
...-- Health information technology programs implemen... full two years after being established, and could...rding to a study by investigators at Weill Cornell...ushal, chief of the Division of Quality and Clinic...
...Stamford-based Olympus Partners is pleased to anno...orp. from The Hansen Corporate Group. Holopack In... immediately change its name to The Ritedose Corpo...ded, filled and sealed in a continuous sterile pro...
...Gundersen Lutheran is the first in the nation to a...ational Quality Measures for Breast Centers(TM) (N... a commitment to provide the highest level of qual...the measurement of breast cancer treatment and out...
...ow Pharmaceutical Marketers Can Leverage Social Me...tives , , PLEASANTON, Calif., March 10 Spigit, ...are for the enterprise, announced today that compa...he Bio/Pharmaceutical Industry at 2:30 p.m. on We...
... A diverse coalition of clergy and lay members fro... conference today to call on U.S. Senators Tom Har...ngressional delegation to support legislation that...ession of Congress, Senator Grassley was not. , ...
Other Medicine News:Health News:Synthetic gene circuit allows precise dosing of gene expression 2Health News:Synthetic gene circuit allows precise dosing of gene expression 3Health News:New York State health IT strategy may be model for the nation 2Health News:New York State health IT strategy may be model for the nation 3Health News:Gundersen Lutheran Breast Center Earns Top National Honor 2Health News:Spigit Enterprise Community Expert to Highlight Enterprise 2.0 Apps for Pharma Companies at Annual CBI eMarketing Forum 2Health News:Spigit Enterprise Community Expert to Highlight Enterprise 2.0 Apps for Pharma Companies at Annual CBI eMarketing Forum 3Health News:Faith Leaders Call on Iowa Members of Congress to Support Legislation to Protect Kids from Tobacco 2Health News:Faith Leaders Call on Iowa Members of Congress to Support Legislation to Protect Kids from Tobacco 3
(Date:11/20/2009)..., MINNEAPOLIS, Nov. 20 B...sults for its first quarter ended September 30, 20...uted share, on revenues of $3,263,000. This compa...ted share, on revenues of $3,168,000 for the first...st quarter results, Biotel President and CEO Steve...
(Date:11/20/2009)..., PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCal...Soligenix or the Company), formerly known as DOR B..., announced today that it has formed a consortium ...x(TM) and other rapidly acting vaccines. Soligenix...nstitute of Allergy and Infectious Diseases (NIAID...
(Date:11/19/2009)..., TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/...e pharmaceutical ingredients (APIs), announced tha...ound Safety Certification from,SafeBridge(R) Consu...,s,competency and proficiency in the safe handling...), and applies to specific laboratories and,produc...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Doctors Efforts to Fight Childhood Obesity Not Working 56256 1Nurses and Retirement Security 3A A Looming Crisis 3F 56253 1Nurses and Retirement Security 3A A Looming Crisis 3F 56253 2Nurses and Retirement Security 3A A Looming Crisis 3F 56253 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 13861 1Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 13861 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 13861 3
...(Nasdaq: CRGN ), a clinical-stage biopharmaceutic... (Copenhagen Stock Exchange: TOPO) announced,today...rom the Phase II,study of belinostat for T-cell ly...ostat on pediatric leukemia cell lines, will be pr... (ASH) 49th Annual Meeting in,Atlanta, GA, on Mond...
...VELCADE in front-line, multiple myeloma to be fe... Society of Hematology (ASH) Annual Meeting...euticals, Inc. (Nasdaq: MLNM ) today announced th...E clinical studies are scheduled to be,featured at...December 8-11,2007. The data will highlight the si...
Other Medicine Technology:CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
Maverick Over-The-Wire 25 mm Catheter
Maverick Over-The-Wire 15 mm Catheter
...ated Phoroptor features lighted dials to make it e... the darkened setting of the exam room. Put away y...the entire process. The Illuminated Phoroptor feat...xis scales that are easier than ever to see. The I...
Illuminated PHOROPTOR Refracting Instrument - Plus Cylinder Black
Medicine Products: